A change of in vivo characteristics depending on specific activity of radioiodinated (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-pIV] as a ligand for sigma receptor imaging

详细信息    查看全文

• 作者：Nasima Akhter ; Kazuhiro Shiba ; Kazuma Ogawa ; Shiro Tsuji ; Seigo Kinuya ; Kenichi Nakajima ; Hirofumi Mori
• 关键词：(+)-p-Iodovesamicol ; Sigma-1 receptor ; Radioligand ; Biodistribution ; High and low specific activity radiolabeled (+)-pIV
• 刊名：Nuclear Medicine and Biology
• 出版年：2008
• 出版时间：January 2008
• 年：2008
• 卷：35
• 期：1
• 页码：29-34
• 全文大小：397 K

文摘

The radioiodinated (+)-p-iodovesamicol [(+)-pIV], which shows a high binding affinity for sigma-1 (σ-1) receptors, is prepared by an exchange reaction. The specific activity (SA) is fairly low and therefore is insufficient for clinical use. In this study, we prepared (+)-[¹²⁵I]pIV with a high SA from tributylstannyl precursor and compared the in vivo characteristics between high and low SA by imaging σ-1 receptors in the central nervous system. In the biodistribution study, a difference in brain accumulation was observed between the two methods. At 30 min postinjection, the brain accumulation (1.58 % ID/g) of low SA [0.6–1.1 TBq/mmol (16–30 Ci/mmol)] (+)-[¹²⁵I]pIV was higher than that (1.34 % ID/g) of high SA [>88.8 TBq/mmol (>2400 Ci/mmol)] (+)-[¹²⁵I]pIV. In the blocking study, the brain uptake of high SA (+)-[¹²⁵I]pIV was reduced more significantly by the coadministration of sigma ligands such as pentazocine, haloperidol or SA4503 than that of low SA (+)-[¹²⁵I]pIV. These results showed that nonspecific binding of high SA (+)-[¹²⁵I]pIV in the brain was lower than that of low SA (+)-[¹²⁵I]pIV, and high SA (+)-[¹²⁵I]pIV bound more specifically to σ-1 receptors in the brain than low SA (+)-[¹²⁵I]pIV. In contrast, in the blood-binding study, high SA (+)-[¹²⁵I]pIV (58.4 % ) bound to blood cells with higher affinity than low SA (+)-[¹²⁵I]pIV (46.0 % ). In metabolite studies, blood metabolites of high SA (+)-[¹²⁵I]pIV (57.3±3.5 % ) were higher than those of low SA (+)-[¹²⁵I]pIV (45.5±4.1 % ) at 30 min postinjection. Higher SA may be apt to bind to blood cells with higher affinity and to be metabolized faster.